French antibody developer Adcytherix closed a €105 million (about $122 million) Series A to take its lead ADC into first‑in‑human studies next year. The funding will support IND‑enabling work and early clinical development, underscoring investor interest in differentiated linker‑payload chemistries and target selection for solid‑tumor ADCs. Adcytherix plans to nominate its clinical candidate and initiate regulatory interactions ahead of a planned Phase 1 launch.